12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gencaro bucindolol: Additional Phase III data

Additional data from the double-blind, North American Phase III BEST trial in 2,708 patients showed that Gencaro reduced the risk of new-onset atrial fibrillation (AF) by 41% vs. placebo. Additionally, a genetic sub-study of 1,040 patients with homozygous arginine at the amino acid position 389 beta-1 adrenergic receptor polymorphism showed that Gencaro significantly reduced the risk of new-onset AF by 74% vs. placebo (p=0.0005). Arca previously said the genotype is the...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >